home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Meetings and Conferences  
 

Beating Malaria 2014 - London

 
  February 12, 2014  
     
 


EuroSciCon, Cineworld: The O2, Peninsula Square, London, London SE10 0DX, United Kingdom
Tuesday, 01 July 2014 09:00 - Thursday, 03 July 2014 17:00


Day 1: Vector Control: Research, Economics and Policy 
The WHO estimations on the burden of malaria do not fully reflect the availability of new tools to fight the diseases nor the multiplicity of parasitological, epidemiology and treatment research- as well as the new thinking on financing- that have been taken place in the last decade. In fact 219 million cases of malaria occur every year around the world and 660.000 people still die - mainly in children under the age of 5.  Moreover, it is evident that current funding levels do not allow for full implementation of the newest and most effective interventions globally: The Roll Back Malaria Partnership estimates that an annual funding gap of about $2.8 billion will need to be filled in order to  to reduce its incidence by 75% and malaria deaths to zero by 2015.  This session aims at understanding the scientific, economic and political implications behind the opportunities and hurdles to stop this killing disease and to achieve the Millennium Development Goals targets. 

Day 2:  Immunology and Vaccination
This session will discuss the mechanisms of immunity and immunopathology in order to facilitate vaccine design and the identification of additional therapies for treatment of severe malaria. There will be plenty of opportunities for debate and networking.

Day 3:  Drug Development and Resistance Control

The prevention of anti-malarial drug resistance is of enormous public health importance. It can be assumed that no therapy currently under development or to be developed in the foreseeable future will be totally protective against malaria.  This session will discuss the development of new treatments for malaria together with the use of current drugs to limit, insofar as it is possible, any further development of resistance. There will be plenty of opportunity for delegates to present their work and network in an informal atmosphere, with a lot of time given for discussion and debate.


Talks include
  • Possible new controlling measures for the pyrethroid-resistant malaria vectors, Dr Hitoshi Kawada, Associate Professor, Institute of Tropical Medicine, Nagasaki University, Japan
  • Development of enantiomerically pure aminoalcohol quinoline derivatives to improve their antimalarial efficiency and assessment of their activity against Plasmodium falciparum in combination with dihydroartemisinin, Dr Catherine Mullié, Assistant Professor , Faculté de Pharmacie, Université de Picardie Jules Verne, France
  • TAntibody longevity to malaria vaccine candidate antigens in immuno-epidemiology studies. Dr Freya Fowkes, Head of Malaria and Infectious Disease Epidemiology, Burnet Institute, Australia
  • Availability and Affordability of Arthemisinin Combination Therapies: do the subsidies work?, Miss Giulia Boselli, Global Health Specialist- Consultant, UK
  • Malaria control in coastal areas - special research and policy needs, Professor Ranjan Ramasamy, Visiting Professor, University of Jaffna, Sri Lanka
  • Antimalarials that improve immune response, Professor José M. Bautista, Complutense University of Madrid, Madrid, Spain
  • Natural products as a source of new drugs and/or herbal treatments for Malaria, Dr Colin Wright, Reader in Pharmacognosy, Bradford School of Pharmacy, University of Bradford, UK
  • Malaria control: the nutraceutical potential of natural cocoa powder, Professor Frederick Addai, Academic Researcher, University of Ghana Medical School, Ghana
  • Citrulline: A novel therapeutic for the cerebral malaria. Dr Irene Gramaglia, Associate Professor, La Jolla Infectious Disease Institute, USA
  • Platelets do not kill blood-stage Plasmodium parasites but function in experimental cerebral malaria pathogenesisDr Joyce M. Velez,  Post-doctoral fellow,  La Jolla Infectious Disease Institute, USA
 
 

The Deadline for abstract submissions for oral presentation is April 10th 2014. Abstracts for poster presentation only can be submitted up to two weeks before the event

Keywords: Malaria,Vector,Biological Control, chemical control,Insecticide, tsetse flies, Habitat Control, LLIN, Anopheles, pyrethroid, resistance, repellent, Anopheles vectors, Environmental change, Malaria, Salinity tolerance, Sea level rise, malaria, reseach, policy, financing, medicines, Vaccine,Antibody,Immunology,Vaccine delivery,Immunotherapy, T cells, Severe malaria, inflammation, B cells, antibody responses,Quinine, malaria, Resistance, Chloroquine,4-aminoquinolone,Amodiaquine,Pyrimethamine,Proguanil, Mefloquine,Atovaquone,combination therapies,   Primaquine , Artemisinin, Halofantrine,Doxycycline, Clindamycin, artemisinin, cryptolepine,traditional antimalarial plants, Antimalarial, Plasmodial control, prophylaxis, Polyphenols, Mefloquine derivatives, stereochemistry,antimalarial efficacy, dihydroartemisinin, combination, Antimalarial, Immune response, Therapy, Parasitostatic, Citrulline, Nitric Oxide, Severe Malaria, cerebral malaria, platelets, aspirin, plasmodium

 

 
 
Organized by: Euroscicon
Invited Speakers:
About the Speakers

Catherine Mullié obtained a PhD in Microbiology and a PharmD at the University of Lille, France, in 1999. After a post-doc year at the Faculté de Medicine in Amiens (Laboratoire d’Immunologie, INSERM-EMI 0351), she became assistant professor at the Faculté de Pharmacie in Amiens in 2000 and joined the LG-2A (Laboratoire de Glycochimie des Antimicrobiens et des Agroressources, FRE-CNRS 3517) in 2008, in the team headed by Pr. Sonnet. The team current research is focused on the development of new antimicrobial and antimalarial drugs, with a special interest in the synthesis and biological evaluation of molecules bearing asymmetric carbons.


Colin Wright 
studied pharmacy at the School of Pharmacy, University of London, and worked in hospital and community pharmacy before returning to carry out research on antimalarial and antiamoebic natural products, obtaining his Ph.D in 1989. He has continued his research at Bradford School of Pharmacy since 1994 particulary on the theme of antimalarial drug development from natural products.

Frederick Addai is an Associate Professor, whose 10-year research in 2004 affirmed healthful gains of consuming good cocoa products.  He has supervised ten graduate studies on health benefits of cocoa, and spawned many more independent studies.  Personal, and community anedcotal experiences with daily consumtpion of cocoa as unsweetned beverage, provoked research that confirms antimalarial activity of natural cocoa.  He has given numerous print and electronic media presentations locally and internationally; including invited talks at the 15th International Cocoa Research Conference (ICRC) in Costa Rica, and 69th General Assembly and Council of Ministers Meeting of the Cocoa Producers’ Alliance (COPAL), Abidjan, La Cote d’Ivoire.

José M. Bautista obtained his Ph.D. in 1987, completed postdoctoral training at the University of London-Royal Postgraduate Medical School, and joined the faculty of Complutense University of Madrid as an Assistant Professor in 1991. He has been visiting scientist at Imperial College of Medicine –Hammersmith Hospital (London), Institute of Genetics and Biophysics  (Naples), University for Developmental Studies (Tamale-Ghana) and Cheikh Anta Diop University (Dakar-Senegal). Full Professor since 2007 at present direct the Department of Biochemistry and Molecular Biology IV at Complutense University of Madrid and the research group Translational Haematology II at the Research Institute Hospital 12 de Octubre in Madrid. Dr. Bautista's research is on improving preclinical models of malaria and highthoughput proteomic methods to determine long term effect of antimalarials including immune response.

 


Britta Urban obtained a PhD at the Bernhard-Nocht Institute for Tropical Medicine in Hamburg, Germany in 1996, investigating complement resistance of Enatamoeba histolytica. She joined the David Roberts' laboratory at Oxford University on a Research Fellowship awarded by the German Research Council to study immune responses toPlasmodium falciparum malaria. She demonstrated that P. falciparum-infected erythrocytes modulate dendritic cell phenotype and function in vitro. These results formed the basis of a Wellcome Trust Career Development Fellowship where she investigated the role of dendritic cells in natural malaria infection in close collaboration with the KEMRI-Wellcome Trust Collaborative Programme in Kilifi, Kenya. She was awarded a Wellcome Trust Senior Research Fellowship in 2006 and has now moved with her group to Kilifi to study cellular immune responses to PfEMP-1. She is particularly interested to investigate whether the phenotypic properties of a given parasite isolate influence the immune response to that isolate.

Giulia Boselli is a passionate Global Health Specialist interested in improving the access to essential medicines. She has started working at the World Health Organization where she designed and implemented a cost effective analysis in Laos for the Neglected Tropical diseases Department. Over the last years she has been enhancing her knowledge on the issues concerning the opportunities and hurdles to making malaria drug available in low income countries, working at Medicines for Malaria Venture (MMV) and at Population Service International (PSI). During her last experience she supervised a research on the availability and affordability of antimalarial drugs in East Africa.

An NHMRC Public Health Fellow, Freya Fowkes is Head of the Malaria and Infectious Disease Epidemiology group at the Burnet Institute. Freya is involved primarily in examining the epidemiology of malaria in particular analysing malaria immuno-epidemiological data from large population-based studies. She completed her doctorate in 2007 at the University of Oxford and has held research associate positions at the New York University School of Medicine and the Walter and Eliza Hall Institute.  Currently, Freya holds an adjunct senior research fellow position at Monash University and is an honorary fellow of the University of Melbourne.

Diana S. Hansen completed her PhD in 1998 at the University of Buenos Aires, Argentina. She turned to malaria research during her postdoctoral training at the Walter and Eliza Hall Institute, Melbourne, where she investigated inflammatory responses involved in the induction of cerebral malaria. Diana is now a Laboratory Head in the Division of Infection and Immunity at WEHI and an Executive Member of the Victorian Infection and Immunity Network. Her main research interests include mechanisms of pathogenesis and immunity to malaria, and she is pursuing those goals using infection models as well as humans studies.
 

Additional confirmed speakers include
  • Dr Britta Urban, Liverpool School of Tropical Medicine, United Kingdom
  • Dr Pierre Guermonprez, Center for Molecular and Cellular Biology of Inflammation, King's College London, United Kingdom
  • Dr Glenn McConkey, Senior Lecturer, School of Biology, University of Leeds, UK
  • Dr Kathy Andrews, Associate Professor, Tropical Parasitology Lab, Griffith University, Australia
  • Dr Mohga Kamal-Yanni, Senior health & HIV policy advisor, Oxfam GB
  • Mr Aditya Jha, Centre for Cellular and Molecular Biology, India
  • Dr Bhargavi Rao, Honorary Clinical Research Fellow, Imperial College London, UK
  • Professor Andrew Taylor-Robinson, Professor of Immunology/Haematology & Deputy Dean Research | School of Medical & Applied Sciences CQ University Rockhampton, Queensland, Australia
 
 
Deadline for Abstracts: The Deadline for abstract submissions for oral presentation is April 10th 2014.
 
Registration:

 Registration includes entry to all the event, lunch and all refreshments, networking opportunities and access to exhibitions


A late registration fee applies after April 20th 2014
 

 

E-mail: enquiries@euroscicon.com
 
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.